Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP256583.RAGZXgppvKapzfHpDY7VQ8czc4Ab3umBa0rt89QYVGdNk130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP256583.RAGZXgppvKapzfHpDY7VQ8czc4Ab3umBa0rt89QYVGdNk130_provenance.
• NP873553.RARYg9OGoze7Zh7iotKIkt9rWo9VXImynSIfOSdcof4LY130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873553.RARYg9OGoze7Zh7iotKIkt9rWo9VXImynSIfOSdcof4LY130_provenance.
• NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802552.RAQ3VxhGx6Tzb1KfvzL-4ss-Uc0ADm14jj1pgvVlhuLIY130_provenance.
• NP358805.RAmwLThqwUNmJlrusKrZp9yHiJ7lR4cSUESjvUFu3SVjE130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP358805.RAmwLThqwUNmJlrusKrZp9yHiJ7lR4cSUESjvUFu3SVjE130_provenance.
• NP950285.RAQg-afuA1j-afI5hPN6YkqdG4651_p_Pa_nY-RZ6jSGM130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950285.RAQg-afuA1j-afI5hPN6YkqdG4651_p_Pa_nY-RZ6jSGM130_provenance.
• NP950286.RAqOyuzISlm8DOTXFNLiDfggrYV51v1k61CvBSCbgrgaY130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950286.RAqOyuzISlm8DOTXFNLiDfggrYV51v1k61CvBSCbgrgaY130_provenance.
• NP950287.RAiGiweynrNPpNr4CTGZT7_hZjwGBgkZCOkrqo9UU3PDM130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950287.RAiGiweynrNPpNr4CTGZT7_hZjwGBgkZCOkrqo9UU3PDM130_provenance.
• NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_provenance.
• NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950291.RAhH5iQLM5H58S0bEg_l8ckSv232QoT7-DkQUKkwQRUDo130_provenance.
• NP358819.RA9hSXEvNyVCPgX6ZDV5hQaUFMM7TLmB3FTWrmRBLsPs8130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP358819.RA9hSXEvNyVCPgX6ZDV5hQaUFMM7TLmB3FTWrmRBLsPs8130_provenance.
• NP817190.RAOtxkQdN-8nKXnE2gfSRu_o7jbW_OimJZz1qy5BA8sHI130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817190.RAOtxkQdN-8nKXnE2gfSRu_o7jbW_OimJZz1qy5BA8sHI130_provenance.
• NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817203.RA6YzSVo557ocYUDTIxs2_D6dg_S23KGFHTGR-5qnq4e0130_provenance.
• NP950288.RAJxyl1rIha9MqiCcITCD1bKG6IJVvpc5DH6wEV3ZRbEg130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950288.RAJxyl1rIha9MqiCcITCD1bKG6IJVvpc5DH6wEV3ZRbEg130_provenance.
• NP950289.RALBc0w39XyceoRFW4H2Tp5BHB88oX8__mVWL0sbe4IQ0130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950289.RALBc0w39XyceoRFW4H2Tp5BHB88oX8__mVWL0sbe4IQ0130_provenance.
• NP950292.RAMYvq60IMwYw-u9f1W8xI2VRblLn_OejjIi9YL8KxyUo130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950292.RAMYvq60IMwYw-u9f1W8xI2VRblLn_OejjIi9YL8KxyUo130_provenance.
• NP802567.RA0UkqnqF-sKOv2xi1SzgH4tGvvxe9lRFs_oVnjIugKxM130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802567.RA0UkqnqF-sKOv2xi1SzgH4tGvvxe9lRFs_oVnjIugKxM130_provenance.
• NP873567.RA8U9Eq6UZmkxjx9j2NCPtwEkQPKt-LZyvWBlvoUqtrgM130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873567.RA8U9Eq6UZmkxjx9j2NCPtwEkQPKt-LZyvWBlvoUqtrgM130_provenance.